Aldeyra Therapeutics Reports Positive Results in Phase 2 Clinical Trial for ADX-629
Aldeyra Therapeutics saw a 12% increase in shares, reaching $3.31, following the announcement of positive topline results from a Phase ...
Aldeyra Therapeutics saw a 12% increase in shares, reaching $3.31, following the announcement of positive topline results from a Phase ...
Sanofi, a leading pharmaceutical company, has announced encouraging trial results for its investigational eczema treatment. This breakthrough comes as a ...